Last updated: June 6, 2026
Executive summary
IOPAMIDOL-300 in plastic container is an injectable, iodinated contrast media product. Market dynamics are driven by imaging utilization, hospital purchasing consolidation, narrow clinical switching tolerance, short re-supply lead times, and heavy price pressure as generic and private-label equivalents expand. Financial trajectory is typically characterized by (1) rapid margin compression after generic/private-label entries, (2) inventory and logistics cost swings tied to raw material and packaging costs, and (3) recurring contract-based price resets rather than durable brand-type pricing.
Because “IOPAMIDOL-300 IN PLASTIC CONTAINER” does not uniquely identify a single FDA-approved product/manufacturer/labeler, no single, complete financial model, revenue history, or basket of competitors can be produced from the available identifiers alone.
What market drives sales for ioPAMIDOL-300 in plastic container?
The commercial engine for iodinated contrast media is imaging demand plus procurement mechanics. Key demand and utilization drivers include:
Imaging utilization and procedure mix
- CT scan volume growth, driven by screening, emergency care, oncology monitoring, and trauma.
- Inpatient vs outpatient mix: outpatient imaging tends to be more competitive on price due to IDN vendor consolidation.
- Specialty CT patterns: contrast use intensity is higher in oncology and vascular workflows than in many routine scans.
Tendering, contract pricing, and hospital formulary placement
- Large integrated delivery networks (IDNs) increasingly lock contrast media into service-level and supply continuity contracts.
- Switching barriers are practical, not clinical. Hospitals emphasize predictable radiology workflow, contrast lot consistency, packaging handling, and turnaround time from distribution.
- “Plastic container” packaging can affect procurement decisions if it improves spill control, shelf presentation, or handling ergonomics.
Supply chain constraints and lead times
- Contrast media sourcing depends on iodinated intermediate availability and capacity scheduling.
- Packaging (especially plastic container supply and line capacity) can become a constraining input during allocation.
- Price and margin are often more sensitive to packaging logistics than to small changes in clinical dosing.
How does packaging in plastic containers affect competitive positioning and pricing?
Plastic containers influence product economics through handling and contracting, not therapeutic performance.
Procurement and distribution
- Hospitals and group purchasing organizations evaluate cases on delivered cost per mL, storage compatibility, and ease of restocking.
- Plastic container formats can reduce handling damage risk versus certain older container types, affecting effective cost of goods and returns.
Switching and radiology workflow
- Practical compatibility with existing administration sets, labeling readability, and handling consistency reduces operational friction.
- Where radiology departments run standardized workflows, packaging familiarity can slow switching even when price differences exist.
When does iopamidol-300 lose exclusivity and what is the impact on pricing?
Exclusivity timelines depend on the specific FDA NDA ANDA sponsor and the Orange Book exclusivity for that exact labeled product. For generic iodinated contrast equivalents, exclusivity is usually not long enough to prevent rapid price resets once approvals land.
Typical post-approval dynamics in iodinated contrast media
- Margin compression accelerates after the first credible generic entrant gains distribution.
- Subsequent entrants compete on contract awards and distribution coverage rather than marketing differentiation.
- Price erosion is often “stepwise” by purchasing region and IDN contract cycles.
What to watch for timing
- FDA approval date of the earliest generic/private-label equivalent for the same concentration (300 mg I/mL class) and comparable container configuration.
- Earliest Paragraph IV or other litigation-driven entry windows for competing and therapeutic equivalent ANDAs.
- Resolution of supply agreements that limit who can service certain IDNs.
What patents protect ioPAMIDOL-300 in plastic container, and how strong is the estate?
Patent protection is usually fragmented across:
- Composition and iodinated agent stabilization approaches
- Container closure system compatibility and manufacturing methods
- Specific formulation, process controls, or method-of-use elements
- Device-administration adjuncts (less common for contrast in this class)
Practical implications for freedom-to-operate
- For contrast media, manufacturing method patents can block process replication even when composition claims are weak.
- Container and process claims can force design-around, changing production steps or stability parameters.
What “strength” looks like in litigation behavior
- If the estate includes manufacturing/process claims, generic sponsors often pursue later-stage design-around pathways and accept time-to-entry risk.
- If claims center on container closure or stability, generic entrants may target alternative container and packaging lots to avoid infringement.
Because this prompt does not specify the exact NDA/ANDA, patent numbers, or labeler, no accurate count of protecting patents or a strength assessment for a defined estate can be produced without producing incomplete or incorrect IP mapping.
What is the Orange Book status of iopamidol-300 in plastic container?
Orange Book status must be product- and labeler-specific. “IOPAMIDOL-300 IN PLASTIC CONTAINER” can correspond to multiple label configurations and applicants.
What to capture in Orange Book analysis (for a complete read)
- Listed drug name and active ingredient
- Dosage form (injection)
- Strength (300 mg iodine/mL class)
- Applicant/labeler
- Patent numbers and expiration dates
- Exclusivity claims: 5-year, 3-year, additional exclusivity where applicable
- Any non-Orange Book patents that nonetheless drive FDA or litigation outcomes
No single Orange Book listing can be tied to the prompt’s phrasing alone.
How many ANDAs and generics compete for iopamidol-300, and who are the main players?
IOPAMIDOL-300 generally competes in a crowded iodinated contrast landscape with:
- Multiple generic iopamidol sponsors
- Private-label equivalents for IDNs
- Potential competition from alternative nonionic iodinated contrast agents (different active ingredients, comparable clinical endpoints)
Competitive structure
- Direct competitors: same active ingredient (iopamidol) and comparable strength with equivalent clinical use.
- Indirect competitors: other nonionic iodinated agents (clinically substitutable by imaging protocols).
Commercial relevance
- Procurement decisions are dominated by total delivered cost and reliable supply, which favors scaled generic and contract manufacturers.
- Market share shifts tend to reflect contract wins and distribution reach, not incremental clinical advantage.
A complete competitor set and market share distribution cannot be generated without the exact FDA listing and labeler.
What generic entry risks exist for iopamidol-300 in plastic container?
Key entry risks for generic iodinated contrast media include:
- Regulatory risk: ANDA approval delays, stability/compatibility issues for the specific container configuration
- Patent litigation risk: patent infringement exposure around process/container closure stabilization
- Supply risk: packaging line availability and lot release timing
- Contract risk: losing initial IDN bids can materially delay volume ramp
Paragraph IV risk profile (typical)
- Contrast media rarely has “blockbuster-style” patent complexity, but process or packaging claims can still be asserted.
- Even when claims are weak, settlements can shift entry timing and volume distribution.
What patent litigation affects iopamidol-300 generic launches?
Litigation outcomes in contrast media typically involve:
- Venue fights and early motions to dismiss
- Design-around arguments for manufacturing steps
- Settlement agreements that set entry dates and supply carve-outs
A litigation map cannot be produced without the specific ANDA/NDA and associated listed patents tied to the exact “plastic container” product.
What settlement agreements or licensing deals change entry timing?
Contrast media settlements tend to be:
- Date-certain entry licensing for ANDA filers
- Supply restrictions or agreement to limit launch geography or accounts during a defined window
- Staggered launches for different package configurations or container volumes
No accurate settlement or licensing deal can be tied to the prompt without identifying the labeler and Orange Book patents.
How does iopamidol-300 compare with alternative iodinated contrast agents on economics?
Economics are influenced by:
- Total contrast cost per study (delivered price and dosing conventions)
- Contract award pricing across IDN radiology formularies
- Switching friction: radiologists may standardize protocols that favor a preferred agent across service lines
Indirect competitive pressure
Even if iopamidol remains a protocol standard, competitor nonionic agents can cap pricing when IDNs renegotiate formularies.
What financial trajectory should be expected for this product class?
For iodinated contrast media and its common generic trajectory:
- Revenue often remains stable to modestly growing in volume terms due to imaging demand.
- Gross margin declines as new entrants expand and contract pricing resets.
- Operating leverage is limited by manufacturing compliance, lot release testing, and logistics.
- Net profitability is highly sensitive to working capital, inventory write-downs, and pass-through price timing for iodinated intermediates and packaging components.
Common quarter-to-quarter drivers
- Contract timing: fiscal-year resets for IDNs and GPOs
- Supply allocation: allocation periods can raise revenue but compress margins if costs rise faster than contract price
- Distribution build: new SKU rollouts in plastic containers can cause temporary inventory and distribution expense
What are the commercial KPIs for managing iopamidol-300 supply and profitability?
Operational KPIs that correlate with financial outcomes:
- Fill rate to key accounts and on-time delivery percent
- Lot release lead time and deviation rate
- Returns and damage rate for container shipments
- Inventory turns by distribution channel
- Contract pricing trend versus benchmark comps in the same region
- Tender win rate and rebate structure
Key data table: factors that move price and revenue for iopamidol-300 plastic container
| Market variable |
Typical direction |
Financial impact |
What to monitor |
| Imaging volume growth |
Up |
Volume revenue up |
CT utilization trends, procedure mix |
| Generic entrant count |
Up |
Price down, margin down |
New ANDA approvals and labeler expansions |
| IDN contracting |
Cyclical reset |
Price step-down at renewals |
Annual and mid-year contract cycles |
| Packaging costs |
Volatile |
COGS up or down |
Plastic container supply, resin/packaging index |
| Supply allocation |
Up during shortages |
Revenue may rise, margin can drop |
Allocation notices, distribution constraints |
| Litigation/settlement-driven entry |
Stepwise |
Entry timing affects pricing |
FDA litigation outcomes tied to listed patents |
Key Takeaways
- The market for iopamidol-300 injectable is procurement-led: pricing erodes in step with generic/private-label entry and IDN contract resets.
- “Plastic container” is mainly a handling and contracting differentiator, with limited ability to sustain premium pricing once direct competitors scale.
- Financial trajectory for this class is usually volume-supported but margin-compressed over time, with profitability sensitive to packaging logistics, supply continuity, and contract timing.
- A precise exclusivity/patent/Orange Book and competitor map requires a specific FDA listing tied to the exact labeler and dosage form identifier; the prompt does not contain that unique identifier, so no accurate patent-expiration or litigation timeline can be stated.
FAQs
- How do GPO contract cycles affect iopamidol-300 pricing?
- What container-closure compatibility issues most often delay generic iodinated contrast approvals?
- How do radiology protocol standardization and radiologist switching behavior influence iopamidol market share?
- Do supply shortages for plastic containers materially change iopamidol-300 gross margin?
- What dosing and concentration differences (e.g., 300 vs other strengths) drive formulary substitution among iodinated contrast agents?
References
- FDA, Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA ANDA approvals and drug shortage information pages. U.S. Food and Drug Administration.
